Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017095924) LIVER-TARGETED PRODRUG COMPOSITIONS AND METHODS OF USING THE SAME
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/095924 International Application No.: PCT/US2016/064216
Publication Date: 08.06.2017 International Filing Date: 30.11.2016
IPC:
A61K 47/54 (2017.01) ,A61P 35/00 (2006.01)
[IPC code unknown for A61K 47/54]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
GEORGETOWN UNIVERSITY [US/US]; 37th & O Streets N.W. Washington, DC 20057, US
Inventors:
YENUGONDA, Venkata, M.; US
Agent:
PABST, Patrea, L.; US
SHYNTUM, Yvonne, Y.; US
HODGES, Robert, A.; US
RAYMOND, Adam, S.; US
MONHEIT, Rivka, D.; US
Priority Data:
62/261,06930.11.2015US
Title (EN) LIVER-TARGETED PRODRUG COMPOSITIONS AND METHODS OF USING THE SAME
(FR) COMPOSITIONS DE PROMÉDICAMENTS CIBLANT LE FOIE ET LEURS MÉTHODES D'UTILISATION
Abstract:
(EN) Disclosed are compositions and methods of delivering a drug to a liver cell or liver tissue in a subject. In some forms, the composition is a prodrug of a drug where the drug, a hydrophilic linker, and a liver-targeted glycol ligand are conjugated together. The hydrophilic linker contains or is coupled to the drug via a cleavable bond such that the cleavable bond is cleaved and the drug released after delivery into a target cell.
(FR) La présente invention concerne des compositions et des méthodes d'administration d'un médicament à une cellule hépatique ou à un tissu hépatique chez un sujet. Sous certaines formes, la composition est un promédicament d'un médicament conjuguant le médicament, un lieur hydrophile, et un ligand de type glycol ciblant le foie. Le lieur hydrophile contient ou est couplé au médicament par l'intermédiaire d'une liaison clivable de façon que la liaison clivable soit clivée et que le médicament soit libéré après administration dans une cellule cible.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)